These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 18284457)
81. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898 [TBL] [Abstract][Full Text] [Related]
82. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Cordoba I; Gonzalez-Porras JR; Such E; Nomdedeu B; Luño E; de Paz R; Carbonell F; Vallespi T; Ardanaz M; Ramos F; Marco V; Bonanad S; Sanchez-Barba M; Costa D; Bernal T; Sanz GF; Cañizo MC Leuk Res; 2012 Mar; 36(3):287-92. PubMed ID: 22133642 [TBL] [Abstract][Full Text] [Related]
83. Allogeneic stem cell transplantation in patients with myelodysplastic syndrome: outcome analysis according to the International Prognostic Scoring System. Rubio S; Martins C; Lacerda JF; Carmo JA; Lourenço F; Lacerda JM Acta Med Port; 2006; 19(5):343-7. PubMed ID: 17376319 [TBL] [Abstract][Full Text] [Related]
84. Evaluating the prognosis of patients with myelodysplastic syndromes. Aul C; Giagounidis A; Germing U; Ganser A Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348 [TBL] [Abstract][Full Text] [Related]
85. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Müller-Thomas C; Schuster T; Peschel C; Götze KS Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067 [TBL] [Abstract][Full Text] [Related]
86. Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system. Cassano E; Giordano M; Riccardi A; Coci A; Cazzola M Haematologica; 1990; 75(2):141-5. PubMed ID: 2358204 [TBL] [Abstract][Full Text] [Related]
87. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Swolin B; Rödjer S; Westin J Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338 [TBL] [Abstract][Full Text] [Related]
88. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study. Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083 [TBL] [Abstract][Full Text] [Related]
89. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099 [TBL] [Abstract][Full Text] [Related]
90. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680 [TBL] [Abstract][Full Text] [Related]
91. Understanding the Myelodysplastic Syndromes. Kouides PA; Bennett JM Oncologist; 1997; 2(6):389-401. PubMed ID: 10388074 [TBL] [Abstract][Full Text] [Related]
92. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585 [TBL] [Abstract][Full Text] [Related]
94. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Verburgh E; Achten R; Louw VJ; Brusselmans C; Delforge M; Boogaerts M; Hagemeijer A; Vandenberghe P; Verhoef G Leukemia; 2007 Apr; 21(4):668-77. PubMed ID: 17301818 [TBL] [Abstract][Full Text] [Related]
95. [Analysis of 259 patients with myelodysplastic syndromes. The Czechoslovak MDS Cooperative Group]. Cas Lek Cesk; 1990 Jul; 129(28):865-71. PubMed ID: 2253265 [TBL] [Abstract][Full Text] [Related]
96. Are we nearer to curing patients with MDS? Sekeres MA Best Pract Res Clin Haematol; 2010 Dec; 23(4):481-7. PubMed ID: 21130411 [TBL] [Abstract][Full Text] [Related]
97. [Primary myelodysplastic syndrome in children]. Kuzmanović M; Bunjevacki G; Rasović N; Vujić D; Mićić D; Guć-Sćekić M; Jovanović V Srp Arh Celok Lek; 2001; 129 Suppl 1():10-6. PubMed ID: 15637984 [TBL] [Abstract][Full Text] [Related]
98. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Konoplev S; Medeiros LJ; Lennon PA; Prajapati S; Kanungo A; Lin P Cancer; 2007 Oct; 110(7):1520-6. PubMed ID: 17701956 [TBL] [Abstract][Full Text] [Related]
99. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. Komrokji RS; Bennett JM Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868 [TBL] [Abstract][Full Text] [Related]
100. What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS). Deeg HJ Leuk Res; 2004 Jun; 28(6):543-4. PubMed ID: 15120927 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]